Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

WHO keeps Bundibugyo Ebola a global health emergency as DR Congo cases pass 11,600

WHO’s Director-General determined on 18 November that the Bundibugyo Ebola outbreak remains a public health emergency of international concern.

Published 21 Nov 2026· 7 minute read
Main building of the World Health Organization headquarters in Geneva seen from the east
Photo: Thorkild Tylleskar / Wikimedia Commons, CC BY-SA 3.0 (cropped). Source · Licence

The World Health Organization said on 20 November 2026 that its Director-General determined on 18 November that the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo remains a public health emergency of international concern. WHO’s latest Disease Outbreak News counts 11,613 confirmed cases as of 17 November, which matters for research offices with staff, partners or trials in the region.

What happened

The determination follows the third meeting of the International Health Regulations Emergency Committee on 17 November, according to the WHO notice. The Director-General concurred with the committee’s advice. WHO says updated recommendations to the Democratic Republic of the Congo and all other States Parties will be issued in the coming days and reported in its next Disease Outbreak News. The previous temporary recommendations were issued on 24 August 2026.

This is a new development since the casrai report of 18 November on the two Bundibugyo vaccine candidates joining the WHO Tumaini trial: that post covered the opening of the committee meeting, and the WHO notice now records its outcome and the updated count.

As of 17 November 2026, WHO reports 11,613 confirmed cases, including 5,678 deaths, a crude case fatality ratio of 48.9 per cent. Cases have been confirmed in 68 health zones across eight provinces, and 48 of those zones reported at least one new case in the previous 21 days. Since the previous notice on 6 November, 945 additional confirmed cases and 480 confirmed deaths have been reported.

Key details

WHO describes sustained, high-level transmission in the Democratic Republic of the Congo, with some areas showing a slight decline. The notice gives these figures for the last 21 days to 17 November, when 1,417 new confirmed cases were reported:

Province New confirmed cases, last 21 days Change reported by WHO
Ituri 668 13% decrease
Nord Kivu 635 8% increase
Haut-Uélé 90 13% increase
Tshopo 20 47% decrease
Nord-Ubangi 4 Not stated

Of the 720 deaths reported since 28 October, 452 occurred in communities and 268 in treatment centres. WHO says this pattern, especially among young children, highlights challenges in early case detection and timely access to care. Sud-Kivu and Sud Ubangi have not reported cases for more than 42 days.

Contact follow-up remains below target. The average share of contacts seen daily over the previous 14 days is 81 per cent against a required 95 per cent. Nord-Kivu is at 77 per cent, Ituri and Haut-Uélé at 86 per cent, Tshopo at 68 per cent and Sud-Ubangi at 63 per cent, while Bas-Uélé (100 per cent) and Nord-Ubangi (99 per cent) meet the threshold.

Outside the Democratic Republic of the Congo, WHO reports that Kenya has recorded nine confirmed cases, including two deaths, all linked to one imported case, and that its last case was discharged on 11 November. Nigeria reported one imported case, which was medically evacuated to Switzerland on 26 October; the patient recovered and was discharged on 11 November, and all 62 identified contacts completed 21-day follow-up. Both countries have begun a 42-day countdown to declaring their outbreaks over. Cases have been reported in five countries since the outbreak was declared on 15 May: the Democratic Republic of the Congo, France, Kenya, Nigeria and Uganda, with the outbreaks in France and Uganda controlled since August.

WHO’s 17 November risk assessment keeps the risk in the Democratic Republic of the Congo at very high and the risk for Kenya and Nigeria at high. It advises against restrictions on travel to, or trade with, affected countries. WHO states that no approved vaccines or specific treatments currently exist for Bundibugyo virus disease.

Background and context

WHO calls this the largest Ebola outbreak ever recorded in the Democratic Republic of the Congo, irrespective of virus species. Al Jazeera, citing Reuters, describes it as the second-largest and second-deadliest Ebola outbreak on record, behind the 2014-2016 West African epidemic that infected more than 28,600 people and killed more than 11,000. The European Centre for Disease Prevention and Control tracks the event separately and, in its 19 November update, gave 11,504 confirmed cases and 5,630 deaths as of 17 November, using data up to 16 November; the figures differ slightly from WHO’s because of different cut-off dates.

Because no vaccine or treatment was developed specifically for the Bundibugyo strain, the research response runs through trials. In his opening remarks to the committee, reported by CIDRAP, WHO Director-General Tedros Adhanom Ghebreyesus said about 900 people in the Democratic Republic of the Congo are enrolled in clinical trials of therapeutics, including a vaccine trial using Ervebo, the vaccine approved for the Zaire strain. He said two candidate vaccines developed specifically against Bundibugyo will be added to an ongoing trial in the coming weeks. The trial is a platform design, a format explained in the casrai comparison of basket, umbrella and platform trials.

Tedros also said that at the start of the outbreak two laboratories could test for the virus and that more than two dozen can now, that close to 2,000 treatment beds are available and that about 3,000 people have recovered. Children have accounted for roughly 30 per cent of all deaths, CIDRAP reports.

Reaction

Africa CDC Director-General Jean Kaseya told Reuters on 15 November that the outbreak is “still not under control” and that, if it is not stopped, it could become the worst Ebola outbreak the world has seen. In the Al Jazeera report he said more than 80 per cent of new cases emerge outside contact lists and over 65 per cent of deaths occur in the community. He added that only $1.3 billion of the $2.9 billion pledged by donors has been released, which he called “a collective failure”.

The UN News report of 13 November quotes the UN Senior Ebola Response Coordinator, Julien Harneis, saying that more people were being killed by Allied Democratic Forces fighters than by Ebola in recent days. Dr Chikwe Ihekweazu, head of WHO’s Health Emergencies Programme, said about 400 to 500 cases were still being identified every week, linked to cases in rural and hard-to-reach areas, while prevention had brought a significant reduction in transmission in earlier hotspots including Bunia.

What it means for researchers, universities and research offices

A continuing emergency of international concern keeps the outbreak inside the framework of public health emergency rules that shape how trials, sample sharing and surveillance work are organised. For research offices the practical points follow from the WHO and UN reporting:

  • Field and travel risk. WHO advises against travel and trade restrictions, while UN responders describe attacks on civilians and health workers in Ituri and Nord Kivu. Institutions with staff or students working with partners in eastern DR Congo will need their own safety and duty-of-care assessment rather than relying on the WHO advice alone.
  • Trial participation. Tedros said candidates designed for Bundibugyo will be added to an ongoing trial, so teams supporting trial sites, laboratories or data management should expect the trial’s scope to change; the phases involved are summarised in the casrai guide to clinical trial phases.
  • Vaccine platforms. For background on one common vaccine technology, see the casrai guide to viral vector vaccines.
  • Funding and logistics. Kaseya’s figure that $1.3 billion of $2.9 billion pledged has been released points to continuing pressure on response and research logistics, including contact tracing, where WHO’s 81 per cent figure is still below its 95 per cent target.

What happens next

WHO says updated temporary recommendations will follow in the coming days and will be reported in its next Disease Outbreak News. Kenya and Nigeria are counting down 42 days toward declaring their outbreaks over, and the two Bundibugyo-specific vaccine candidates are due to join the Tumaini trial in the coming weeks, as Tedros said on 17 November.

Sources

Ask CASRAI · full access

Ask about this story

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →